Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?.

Author: Jihye PARK ¹ ; Jae Hee CHEON
Author Information

1. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. geniushee@yuhs.ac
Publication Type:Editorial
MeSH: Adalimumab*
From:Intestinal Research 2017;15(3):263-265
CountryRepublic of Korea
Language:English
Abstract: No abstract available.